Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 丽珠医药集团股份有限公司是集医药研发、开发、生产、销售为一体的综合性医药企业集团,创建于1985年1月,注册资本约为3亿元。丽珠集团毗邻港澳,借力广深,区位优势明显。集团A、B股于1993年相继上市。丽珠医药集团已经建立了覆盖国内市场的营销网络;随着质量体系的持续提高,随着销售的快速增长,随着产能的不断扩大,随着新厂建设步伐的加快,丽珠即将整体搬迁新厂,新厂占地42.7万平方米,建造国际一流的现代化制药生产基地,这标志着丽珠集团从此进入了一个全新的发展阶段,丽珠集团将成为国内领先、国际一流的现代化制药龙头企业。丽珠集团已经跻身中国上市企业投资10强,最佳上市企业治理10强、广东省高新技术企业、广东省医药行业杰出贡献企业、中国制药工业(销售)百强企业第46名、广东省医药工业综合实力50强。目前,丽珠集团正在进行战略转型,一方面继续保持既有的优势领域并做大增量,另一方面快速进入代表当今和未来国际医药发展方向的单抗和疫苗的前沿阵地,实现战略转型,朝着中国民族制药工业最卓越的目标前进,全力建设致力于人类生命常青事业的伟大公司。 | ||||||||||||||||||||||||
Main Business | 医药产品的生产,营销及科研领域,产品涉及化学药品、生化药品、生物工程药品 、化学合成原料药、抗生素、微生态制剂、中成药、诊断试剂、生物活性材料等各个医药领域的上百个品种 | ||||||||||||||||||||||||
Legal Representative | 朱保国 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 杨亮 | ||||||||||||||||||||||||
Solicitors | 北京国枫律师事务所 | ||||||||||||||||||||||||
Auditors | 瑞华会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0756-8135990;0756-8135992 | ||||||||||||||||||||||||
Fax No | 0756-8891070 | ||||||||||||||||||||||||
Website | www.livzon.com.cn | ||||||||||||||||||||||||
LIVZON_GROUP@livzon.com.cn;yangliang2014@livzon.com.cn;yedelong@livzon.com.cn | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 28/10/1993 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 2.100 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 1.350 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 15.200 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 22.699B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |